GLP-1 nausea peaks weeks 1–4 after each dose bump
Nausea on a new GLP-1 dose is not random — it follows a curve. Peak intensity at 48–72 hours after the first injection of the new dose, slow fade through week 3, near-baseline by week 4. Knowing the shape lets you set expectations and pace solid food intake.
The standard curve
| Day after first injection of new dose | Typical nausea level (1–10) | What's going on |
|---|---|---|
| 0–24 h | 1–3 | Plasma still building; mild fullness |
| 24–48 h | 3–6 | Plasma approaching peak; gastric emptying slows |
| 48–72 h | 5–8 (peak) | Maximum effect on gastric emptying; most likely to vomit |
| Day 4–7 | 4–6 | Persistent but adapting |
| Week 2 | 2–4 | Daily but tolerable; symptoms cluster around the next injection |
| Week 3 | 1–3 | Mild background; specific triggers (large meals, fat) provoke flares |
| Week 4 | 0–2 | Near baseline; mostly tolerant |
Why it peaks at 48–72 hours
Semaglutide and tirzepatide reach peak plasma at roughly 24–48 hours after injection. Gastric emptying slows in parallel. The combination — peak plasma plus maximum gastric retention — creates the 48–72 hour window. By hour 96, plasma starts declining (half-life ~115–165 hours), and by injection 2 the gut has started to adapt.
Why each dose bump resets the curve
Tolerance is dose-specific. The gut adapts to the current dose by downregulating GLP-1 receptors in gastric tissue. When the dose jumps — 0.25 to 0.5 mg, 0.5 to 1.0 mg, etc. — the receptors are no longer fully covered by the previous adaptation level. Some adaptation transfers (which is why bumps after the second feel less awful than bumps after the first), but most of the 4-week curve repeats.
Behaviors that flatten the curve
- Smaller meals through week 1. Gut capacity is at its lowest. Eat 60–70% of what feels "normal."
- Lower fat in the peak window. Fat slows gastric emptying further. The 48–72 hour fatty-meal vomit is a textbook event.
- Hydration without volume. Sip water between meals. A 500 mL glass after dinner is a trigger.
- Evening injection. Shifts peak symptoms into sleep hours. Has modest evidence but consistent user reports.
- Anti-nausea PRN. Ondansetron 4 mg as needed in the 48–72 hour window. Effective for most users. Discuss with prescriber.
The hold decision
The labeled minimum hold at each step is 4 weeks. If at week 3 you're still at peak intensity (nausea level 5+/10 daily), the gut hasn't adapted. Advancing on schedule guarantees a worse week 1 at the next dose.
When it isn't the curve
Symptoms outside the curve's shape are worth pausing for:
- Severe abdominal pain, especially radiating to the back — workup for pancreatitis. Stop the drug and call your prescriber.
- Vomiting that persists past 5 days at any dose — risk of dehydration and AKI.
- New gallbladder-region pain, especially right-upper-quadrant after fatty meals — workup for cholecystitis or gallstones (GLP-1s elevate risk).
- Nausea that re-emerges after months of tolerance — usually indicates a missed dose, but persistent return is worth a clinical check.
FAQ
Does eating before the injection prevent nausea?
Marginally. Solid food in the stomach at injection time slows the rate at which plasma peaks, which can take the edge off the 48–72 hour peak. Light meal, not a large one.
Why is my third injection worse than my second?
Likely a dose bump in the middle. If dose is constant and the third is worse, look at meal size, fat, or alcohol on the day. Plain dose-related curve declines from injection to injection on a constant dose.
Can I use ginger or peppermint for the nausea?
Mild help, especially for the background-level symptom. Won't blunt the 48–72 hour peak meaningfully. Use as adjunct, not replacement, for the practical behaviors.
Is the nausea ever permanent?
Effectively no. Persistent severe nausea past week 4 at a stable dose almost always indicates the dose is wrong (too high) or an unrelated GI problem. Don't accept "this is just my GLP-1" past week 4.
Related reading
See your own nausea curve
Peptide Protocol logs daily symptom severity per dose. The chart tells you whether you're on the standard curve or need to hold.
Get the iPhone app →Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.